and extracts the following text as a script body — the dev server then fails its dependency scan with `Expected ";" but found "non"` from the words "non-allowlisted hosts", which breaks e2e. So, what this buys, so nobody reads more or less into it: blocks external `script src=` from non-allowlisted hosts blocks injected inline scripts — each one is pinned by hash blocks fetch/XHR/WebSocket exfiltration (connect-src allowlist) blocks form-action, base-uri, object-src vectors does not stop image-based exfiltration — img-src must allow https: because event media comes from arbitrary publishers' og:image The cost of hashing is that an inline script edited after the hashes are computed is silently refused by the browser. That is why the violation reporter below exists: report-uri/report-to are ignored in a meta element and Pages serves no CSP header, so violations are caught in-page and sent to PostHog instead (src/lib/csp-report.ts, #241). frame-ancestors is deliberately NOT in this string: it is ignored in a meta element and browsers log a warning about it on every page load. It lives in public/_headers instead, ready for a CDN in front of Pages. X-Frame-Options (set there too) is the clickjacking control that actually applies today. */ }
approval high confidence

FDA Approves Pirtobrutinib (Jaypirca) for Previously Untreated CLL/SLL Without 17p Deletion — First Non-Covalent BTK Inhibitor in First Line

| Cancer Breakthroughs

On October 2, 2026, the FDA approved Lilly's pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion. Approval rests on the global randomized phase 3 BRUIN CLL-313 trial (282 patients): pirtobrutinib reduced the risk of progression or death by 80% versus bendamustine-rituximab, with median PFS not reached versus 33.5 months and overall response rates of 94% versus 81%. It is the first non-covalent BTK inhibitor approved in the first-line setting.

Media

FDA approval of pirtobrutinib for first-line CLL/SLL
FDA approval of pirtobrutinib for first-line CLL/SLL — OncoDaily

Sources

View full Cancer Breakthroughs dashboard